Engineered immune cells aim to repair damaged hearts

NCT ID NCT07505199

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This early-stage trial tests a new cell therapy for people with heart failure caused by blocked arteries. The treatment uses the patient's own immune cells, engineered to target scar tissue in the heart. The study will check safety and whether it can improve heart function in 15 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FAP-targeted immunosuppressive CAR-DC cells (iCDC)
What this could lead to: If it works, this could point toward a new treatment for heart failure caused by blocked arteries, potentially improving heart function.
What could go wrong: This is a very early Phase 1 trial with only 15 people, so it is mainly checking safety. The treatment may not improve heart function, and there could be side effects from the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELL THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiomyopathy dilated cardiomyopathy myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CELL THERAPY ISCHEMIC CARDIOMYOPATHY

Contacts and locations

Locations

Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING

Hangzhou, Zhejiang / 浙江, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.